LEVOPHTA
CHAUVIN
Identification
- Active ingredient (INN)
- LEVOCABASTINE
- Internal code
- 17 B 109
- Country of Origin
- France
- Pharmaceutical form
- Eye Drops Solution
- Prescription List
- Regulated (List II)
- Packaging
- flacon/5ml
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Levocabastine is a selective second-generation
H1-receptor antagonist used for allergic conjunctivitis.
Levocabastine was discovered at Janssen
Pharmaceutica in 1979.
Indications
As an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Also used as a nasal spray for allergic rhinitis.
Pharmacodynamics
Levocabastine is a selective histamine
H1-receptor antagonist exerting inhibitory effects on the release of chemical mediators from mast cells and on the chemotaxis of polymorphonuclear leukocytes and eosinophils.
Both histamine and antigens induced conjunctivitis can be inhibited by levocabastine.
Levocabastine can also reduce symptoms of allergic rhinitis by preventing an increase in vascular permeability of nasal mucosa.
Mechanism of Action
H1 receptor Antagonist Neurotensin receptor type 2 Partial antagonist.
Absorption
After instillation in the eye, levocabastine is systemically absorbed, albeit at low levels.
Metabolism
Mostly unchanged. 10-20% is metabolized to the acylglucuronide of levocabastine.
Half-life
hours (after oral administration).
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
Adverse effects include visual disturbances, dry mouth, cough, nausea, eyelid edema and lacrimation.